Mannkind Corp. (MNKD): Representatives of Mannkind will present later in the week, too, and investors will be seeking an update on the Afrezza trials. Afrezza is being developed as an inhaled insulin alternative to needle-delivered insulin and was last denied an FDA approval two years ago when the FDA demanded new trials be conducted utilizing the company's next-generation inhaler. Founder Al Mann recently injected new cash into the company but a partner is still being sought. MNKD has gained about twenty five percent since Thanksgiving, although recent history has shown that this stock's volatile peaks and valleys are best to play as trades, even if still holding onto a core group of long-term shares for the future. Should be a relatively hot one to watch this year.

http://vfcsstockhouse.com/blog/article/-weekly-stock-watch-week-of-7-january-goog-aa-wfc-msft-yhoo-jpm-amrn-tev-azn-pfe-dndn-mdvn-sny-jnj-mnkd-mric-bsx-trov-ino-cvm-onvo-siri-lmca